Loading

Please wait...

Gazyva

Generic Name: obinutuzumab (OH bi nue TOOZ ue mab)
Brand Names: Gazyva
Gazyva (obinutuzumab) is a cancer medication used to treat chronic lymphocytic leukemia. Includes Gazyva side effects, interactions and indications.
  • Prescription Settings

Prices and coupons of Gazyva

Current Location: 20149 (Ashburn)
Change Location?

Enter your zip code


Please wait while the prices are loaded...

Don’t see your pharmacy listed? Most pharmacies accept our discounts, so have your pharmacist enter this coupon to see if you will save money:

Drug Information:
Gazyva (obinutuzumab) is a monoclonal antibody that affects the actions of the body's immune system. Obinutuzumab strengthens your immune system to help your body fight against tumor cells. Gazyva is used in combination with another cancer medicine called chlorambucil to treat chronic lymphocytic leukemia. Gazyva is also used in combination with other cancer medicines to treat follicular lymphoma (a type of non-Hodgkin lymphoma), or to help delay the progression of this disease. If you've ever had hepatitis B, using Gazyva can cause this virus to become active or get worse. Tell your doctor if you don't feel well and you have right-sided upper stomach pain, vomiting, loss of appetite, or yellowing of your skin or eyes. Learn more

Gazyva Side Effects

Gazyva Side Effects

Note: This document contains side effect information about obinutuzumab. Some of the dosage forms listed on this page may not apply to the brand name Gazyva.

In Summary

Common side effects of Gazyva include: infection, fever, hyperkalemia, hypocalcemia, hypokalemia, hypophosphatemia, and neutropenia. See below for a comprehensive list of adverse effects.

For the Consumer

Applies to obinutuzumab: intravenous solution

Warning

Intravenous route (Solution)

Hepatitis B virus (HBV) reactivation can occur in patients receiving obinutuzumab or other CD20-directed cytolytic antibodies, which can progress to life-threatening or fatal fulminant hepatitis or hepatic failure. Screen patients at baseline for HBV infection. Monitor HBV-positive patients during and after treatment with obinutuzumab. If HBV reactivation occurs, discontinue obinutuzumab and concomitant medications. Life-threatening or fatal progressive multifocal leukoencephalopathy has also been reported.

Along with its needed effects, obinutuzumab (the active ingredient contained in Gazyva) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking obinutuzumab:

More common

  • Back pain
  • black, tarry stools
  • bleeding gums
  • blood in the urine or stools
  • chest tightness
  • chills
  • cough
  • fever
  • flushing
  • headache
  • hoarseness
  • lower back or side pain
  • nausea
  • painful or difficult urination
  • pale skin
  • pinpoint red spots on the skin
  • sore throat
  • trouble breathing
  • troubled breathing with exertion
  • ulcers, sores, or white spots in the mouth
  • unusual bleeding or bruising
  • unusual tiredness or weakness
  • vomiting

Less common

  • Joint pain, stiffness, or swelling
  • stomach pain
  • swelling of the feet or lower legs

Incidence not known

  • Blurred vision
  • confusion
  • dark urine
  • dizziness
  • drowsiness
  • general tiredness and weakness
  • light-colored stools
  • seizures
  • upper right abdominal or stomach pain
  • yellow eyes and skin

Some side effects of obinutuzumab may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

Incidence not known

  • Bleeding, blistering, burning, coldness, discoloration of the skin, feeling of pressure, hives, infection, inflammation, itching, lumps, numbness, pain, rash, redness, scarring, soreness, stinging, swelling, tenderness, tingling, ulceration, or warmth at the injection site

For Healthcare Professionals

Applies to obinutuzumab: intravenous solution

Cardiovascular

Common (1% to 10%): Hypertension, cardiac failure

Frequency not reported: Worsening of preexisting cardiac conditions with fatalities, atrial fibrillation

Hematologic

Very common (10% or more): Neutropenia (41%), thrombocytopenia (15%), anemia (12%)

Common (1% to 10%): Leukopenia, lymph node pain

Hepatic

Very common (10% or more): AST (SGOT) increased (28%), ALT (SGPT) increased (25%)

Metabolic

Very common (10% or more): Hypophosphatemia (36%), hypoalbuminemia (33%), hypoproteinemia (32%), hypocalcemia (32%), hypocalcemia (32%), hyperuricemia (28%), hyponatremia (26%), hyperkalemia (23%), hypernatremia (16%) alkaline phosphatase increased (16%), decreased appetite (14%)

Common (1% to 10%): Tumor lysis syndrome, hyperuricemia

Musculoskeletal

Common (1% to 10%): Arthralgia, back pain, musculoskeletal chest pain, pain in extremity, bone pain

Nervous system

Very common (10% or more): Headache (18%), asthenia

Frequency not reported: Progressive multifocal leukoencephalopathy (PML)

Other

Very common (10% or more): Pyrexia (18%)

Renal

Very common (10% or more): Creatinine increased (30%)

Respiratory

Very common (10% or more): Cough (26%), pneumonia (14%), sinusitis (12%), upper respiratory tract infection

Common (1% to 10%): Rhinitis, pharyngitis, nasopharyngitis, lung infection, nasal congestion, rhinorrhea, lung infection

Immunologic

Very common (10% or more): Positive test for anti-obinutuzumab (the active ingredient contained in Gazyva) antibodies (13%)

Common (1% to 10%): Infection (9%)

Frequency not reported: Hepatitis B reactivation, immunogenicity

Dermatologic

Very common (10% or more): Alopecia (13%)

Common (1% to 10%): Pruritus, night sweats, eczema

Local

Very common (10% or more): Infusion related reactions (69%)

Ocular

Common (1% to 10%): Ocular hyperemia

Genitourinary

Common (1% to 10%): Urinary tract infection, urinary incontinence, dysuria

Oncologic

Common (1% to 10%): Squamous cell carcinoma of the skin

Gastrointestinal

Very common (10% or more): Constipation (19%), diarrhea (10%)

Common (1% to 10%): Oral herpes, dyspepsia, colitis, hemorrhoids

Hypersensitivity

Frequency not reported: This drug can cause serious infusion reactions. See Warnings.

Editorial References and Review

Medically reviewed by BestRx Medical Team Last updated on 1/1/2020.

Source: Drugs.com Gazyva